In a major consolidation move, Eldorado Gold announces a definitive agreement to acquire Canadian copper-gold developer Foran Mining, positioning the combined entity as a significant near-term producer with a diversified North American and European asset base.
Tesla's stock dipped amid reports of potential Ford-Xiaomi joint venture talks, highlighting growing competitive pressures from Chinese EV makers and the complex geopolitical landscape shaping the auto industry's future.
As Baidu pivots from its search engine roots, its heavy investments in autonomous vehicle technology are beginning to yield operational results, reshaping analyst views and sparking fresh valuation discussions amidst fierce AI competition.
Reports of discussions between Ford Motor Company and Chinese tech giant Xiaomi over a potential electric vehicle partnership have ignited industry speculation, despite both firms denying any imminent deal. The talks underscore the complex interplay of technology, geopolitics, and market access shaping the global EV race.
Huntington Bancshares has finalized its merger with Cadence Bank, a move that significantly extends its regional footprint into Texas and the Southern U.S. and reshapes its competitive standing.
As sports betting handles hit record highs, data reveals a stark contrast: the average bettor consistently loses, while disciplined investing in instruments like index funds builds wealth over time.
Palantir Technologies prepares to release its fourth-quarter financial results, with analysts forecasting significant growth despite recent pressure on its stock and broader software sector concerns.
A Foxboro woman's two-year struggle with a defective high-end oven underscores the enduring power of state consumer protection laws, even after a manufacturer's warranty expires.
Fifth Third Bancorp has finalized its acquisition of Comerica in under four months, a swift consolidation that underscores a new era of accelerated bank mergers driven by regulatory shifts and the relentless pursuit of scale.
Albertsons' retail media division opens its first NYC office and unveils a new logo, signaling a significant expansion and strategic push to deepen ties with advertisers and agencies in the competitive retail media landscape.
Newly released video evidence shows Islamic State fighters moving unchallenged among aircraft at Niamey's Diori Hamani International Airport, igniting regional tensions and raising urgent questions about security in the Sahel.
As the Federal Reserve prepares for a potential policy shift in 2026, analysts flag real estate, financials, energy, and consumer discretionary as vulnerable sectors. Structural challenges and changing macroeconomic conditions could pressure performance despite broader market gains.
Tesla's sales decline in Europe continues despite new lower-cost models, while industry buzz swirls around a hotly denied report of potential Ford-Xiaomi collaboration. Meanwhile, U.S. dealers show surprising pragmatism toward the EV transition.
As the 2027 deadline for Swift's Case Management standard approaches, banks face a strategic inflection point. Early adopters of native processing are poised to unlock operational resilience and revenue growth, while laggards risk entrenched inefficiency and competitive decline.
Aptiv reported record fourth-quarter revenue of $5.2 billion, a 3% increase, as the automotive technology leader prepares to spin off its Electrical Distribution Systems business as the independent company Versagen on April 1, 2026.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
